RPG Life Sciences Ltd
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
- Market Cap ₹ 3,327 Cr.
- Current Price ₹ 2,011
- High / Low ₹ 2,725 / 1,731
- Stock P/E 29.7
- Book Value ₹
- Dividend Yield 0.99 %
- ROCE %
- ROE %
- Face Value ₹ 8.00
Pros
Cons
- Earnings include an other income of Rs.95.3 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 653 | |
| 494 | |
| Operating Profit | 160 |
| OPM % | 24% |
| 95 | |
| Interest | 1 |
| Depreciation | 21 |
| Profit before tax | 233 |
| Tax % | 21% |
| 183 | |
| EPS in Rs | 110.79 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 34% |
| 3 Years: | 36% |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Capital Employed (ROCE) % ・Standalone data |
|
|||||||||
| Return on Equity (ROE) % ・Standalone data |
||||||||||
| Number of Manufacturing Facilities Number ・Standalone data |
||||||||||
| Doctor Reach (Total) Number ・Standalone data |
||||||||||
| Employee Happiness Score % ・Standalone data |
||||||||||
| Indian Pharmaceutical Market (IPM) Ranking Rank ・Standalone data |
||||||||||
| New Product Launches (Domestic) Number ・Standalone data |
||||||||||
| Sales Force Productivity (PCPM - Per Core Per Month) Rs. Lakhs ・Standalone data |
||||||||||
| Super Specialist Doctor Reach Number ・Standalone data |
||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6h
-
Board Meeting Intimation for The Company Has Informed BSE That The Meeting Of The Board Of The Company Is Scheduled On 29Th April, 2026
1d - Board meets April 29, 2026 to approve FY26 audited results and consider dividend.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 20 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Compliance certificate under Regulation 74(5) for quarter ended 31 March 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Apr - Newspaper Advertisement in respect to Special Window opened for lodgment of transfer and dematerialization request(s).
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025Transcript PPT REC
-
Jul 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Apr 2025Transcript PPT REC
-
Nov 2024TranscriptAI SummaryPPT
-
Sep 2024TranscriptPPTREC
-
Jul 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Jan 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Jun 2019TranscriptAI SummaryPPT
-
Jun 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Jun 2017TranscriptAI SummaryPPT
-
Nov 2016TranscriptAI SummaryPPT
-
Jun 2016TranscriptAI SummaryPPT
Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs